Journey Medical (DERM) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Journey Medical Corp  (NASDAQ: DERM)

Select the Financial Report: Select the Period:


Description of Journey Medical's Business Segments


Journey Medical Corp is a biopharmaceutical organization dedicated to the development and commercialization of innovative products aimed at addressing various dermatological conditions. The company focuses on a wide range of therapeutic areas, primarily within the dermatology sector. Here’s an extensive overview of the segments, products, and services offered by Journey Medical Corp:

Segments:

1. Prescription Dermatology Products:
- Journey Medical Corp primarily specializes in prescription drugs formulated to treat skin conditions. These products can be targeted towards a variety of dermatological issues, including but not limited to acne, eczema, psoriasis, and other chronic skin diseases.

2. Consumer Health Products:
- The company may also have segments that focus on over-the-counter skincare and wellness solutions aimed at improving skin health. These products serve as adjuncts to prescription treatments and cater to consumers seeking easier access to skin-related solutions.

3. Clinical Research:
- Journey Medial Corp emphasizes research and development, enriching the pharmaceutical landscape through novel formulations and therapies. This segment encompasses conducting clinical trials and studies aimed at ensuring the safety and efficacy of new dermatological products.

Products:

1. Topical Treatments:
- Creams and Ointments: Designed to deliver medication directly to the affected area of the skin; used widely for conditions like psoriasis and eczema.
- Gels and Foam: Providing innovative delivery systems for certain medications that can enhance absorption and minimize irritation, such as acne treatments.

2. Oral Medications:
- Tablets or capsules designed for systemic treatment of severe dermatological disorders that may not be adequately managed with topical therapies alone.

3. Biologics:
- Target-specific therapy options may be available as part of the roster, focusing on conditions that require advanced therapeutic strategies involving immune modulation.

4. Combination Therapies:
- Journey Medical Corp might offer products that utilize combined mechanisms of action, providing comprehensive treatment plans for complex skin issues.

Services:

1. Patient Support Programs:
- Offering educational resources and support services to improve treatment adherence, understanding of dermatological conditions, and management strategies. Programs may include direct communication with healthcare professionals and access to informational materials.

2. Healthcare Professional Engagement:
- Journey Medical Corp likely invests resources into educating healthcare providers about its product line through workshops, seminars, and direct communication to ensure they are well-informed about the latest advancements and product uses.

3. Clinical Trials and Research Initiatives:
- Actively involved in conducting clinical trials, the company collaborates with various institutions and stakeholders to gather data on product efficacy and safety, contributing to the growing body of dermatological science.

4. Regulatory Support:
- Working through the intricacies of regulatory requirements to maintain compliance and ensure that all products meet the necessary health and safety standards imposed by regulatory bodies.

Journey Medical Corp is positioned strategically within the healthcare landscape, focusing on innovative therapeutic options and comprehensive support for both patients and healthcare providers. Their dedication to research, patient education, and community engagement plays a crucial role in their operational strategy and overall mission to enhance dermatological care.


Composition of Journey Medical Corp Revenues by Segments

 
Emrosi    39.17 % of total Revenue
Qbrexza    31.5 % of total Revenue
Accutane    20.76 % of total Revenue
Foam franchise products Amzeeq Zilxi    6.58 % of total Revenue
Other legacy    1.74 % of total Revenue
Dermatological segment    100 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Emrosi 6.25 39.17 %
Qbrexza 5.03 31.5 %
Accutane 3.31 20.76 %
Foam franchise products Amzeeq Zilxi 1.05 6.58 %
Other legacy 0.28 1.74 %
Dermatological segment 15.96 100 %
Total 15.96 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Emrosi 202.03 % -
Qbrexza -2.58 % -
Accutane -9.33 % -
Foam franchise products Amzeeq Zilxi -31.19 % -
Other legacy -61.9 % -
Dermatological segment 21.48 % -
Total 21.48 % -74.2 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Dermatological segment -2.23 -
Total -2.23 -




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Dermatological segment - -
Total - -




Annual Report on Journey Medical Corp Divisions, Sales by Country

 
Emrosi   Emrosi Segment contribution to total sales 23.84 % of total Revenue
Qbrexza   Qbrexza Segment contribution to total sales 40.44 % of total Revenue
Accutane   Accutane Segment contribution to total sales 20.83 % of total Revenue
Foam franchise products Amzeeq Zilxi   Foam franchise products Amzeeq Zilxi Segment contribution to total sales 9.47 % of total Revenue
Other legacy   Other legacy Segment contribution to total sales 4.43 % of total Revenue
Dermatological segment   Dermatological segment Segment contribution to total sales 100 % of total Revenue
Cutia supply agreement   Cutia supply agreement Segment contribution to total sales 0.98 % of total Revenue
Royalties on sales of Amzeeq by Cutia   Royalties on sales of Amzeeq by Cutia Segment contribution to total sales 0.02 % of total Revenue


Twelve months ended 2025
DERM s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Emrosi 14.75 23.84 %
Qbrexza 25.01 40.44 %
Accutane 12.88 20.83 %
Foam franchise products Amzeeq Zilxi 5.86 9.47 %
Other legacy 2.74 4.43 %
Dermatological segment 61.86 100 %
Total 61.86 100 %
Cutia supply agreement 0.61 0.98 %
Royalties on sales of Amzeeq by Cutia 0.01 0.02 %


Twelve months ended 2025
DERM s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Dermatological segment -11.43 -
Total -11.43 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Qbrexza -0.4 % -
Accutane -33.62 % -
Foam franchise products Amzeeq Zilxi -11.92 % -
Other legacy -30.85 % -
Dermatological segment 10.2 % -
Total 10.2 % -
Amzeeq - -
Zilxi - -
Cutia License Agreement - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.